Clinical utility of liquid diagnostic platforms in non-small cell lung cancer

Oncologist

Volumn 21, Issue 9, 2016, Pages 1121-1130

  Levy, Benjamin ^a   Hu, Zishuo I ^a   Cordova, Kristen N ^b   Close, Sandra ^c   Lee, Karen ^a   Becker, Daniel ^d  

^a MOUNT SINAI HEALTH SYSTEM   (United States)

^b Oncology Resource Group   (United States)

^c GenEngine Group   (United States)

^d NEW YORK UNIVERSITY   (United States)

Author keywords

Cell free DNA; Circulating tumor cells; Liquid diagnostics; MicroRNA; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; GEFITINIB; MICRORNA; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; CELL FREE NUCLEIC ACID; TUMOR MARKER;

ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CELL HETEROGENEITY; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; FINE NEEDLE ASPIRATION BIOPSY; HUMAN; LUNG BIOPSY; MASS SPECTROMETRY; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; TREATMENT RESPONSE; BLOOD; GENOTYPE; MUTATION; PATHOLOGY; PROGNOSIS; PROTEOMICS; TUMOR EMBOLISM;

BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL-FREE NUCLEIC ACIDS; GENOTYPE; HUMANS; MUTATION; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROTEOMICS;

EID: 84987962168     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0082     Document Type: Article

References (96)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2. Beiter T, Fragasso A, Hudemann J et al. Short-term treadmill running as a model for studying cell-free DNA kinetics in vivo. Clin Chem 2011;57:633-636.
3. Atamaniuk J, Kopecky C, Skoupy S et al. Apoptotic cell-free DNA promotes inflammation in haemodialysis patients. Nephrol Dial Transplant 2012;27:902-905.
4. García Moreira V, de la Cera Martínez T, Gago González E et al. Increase in and clearance of cellfree plasma DNA in hemodialysis quantified by realtime PCR. Clin Chem Lab Med 2006;44:1410-1415.
5. Antonatos D, Patsilinakos S, Spanodimos S et al. Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci 2006;1075: 278-281.
6. Shimony A, Zahger D, Gilutz H et al. Cell freeDNA detected by a novel method in acute ST-elevation myocardial infarction patients. Acute Card Care 2010;12:109-111.
7. Tsai NW, Lin TK, Chen SD et al. The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke. Clin Chim Acta 2011;412:476-479.
8. Diaz LA Jr., Bardelli A. Liquid biopsies: Genotyping circulating tumor DNA. J Clin Oncol 2014;32: 579-586.
9. Ilie M, Hofman V, Long E et al. Currentchallenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med 2014;2:107.
10. Diehl F, Schmidt K, Choti MA et al. Circulating mutant DNA to assess tumor dynamics. Nat Med 2008;14:985-990.
11. Leon SA, Shapiro B, SklaroffDMet al. FreeDNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977;37:646-650.
12. Rolfo C, Castiglia M, Hong D et al. Liquid biopsies in lung cancer: The new ambrosia of researchers. Biochim Biophys Acta 2014;1846: 539-546.
13. Kimura H, Suminoe M, Kasahara K et al. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). Br J Cancer 2007;97: 778-784.
14. Douillard JY, Ostoros G, Cobo M et al. Gefitinib treatment in EGFR mutated Caucasian NSCLC: Circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol 2014;9:1345-1353.
15. Mao C, Yuan JQ, Yang ZY et al. Blood as a substitute for tumor tissue in detecting EGFR mutations for guiding EGFR TKIs treatment of nonsmall cell lung cancer:Asystematic review and meta-analysis. Medicine (Baltimore) 2015;94: e775.
16. Luo J, Shen L, Zheng D. Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: A systematic review and meta-analysis. Sci Rep 2014;4:6269.
17. Sacher AG, Paweletz C, Alden R et al. A prospective study of rapid plasma genotyping utilizing sequential ddPCR and NGS in newly diagnosed advanced NSCLC patients. Paper presented at the World Conference Lung Cancer (WCLC); 2015, ORAL 38.01; Denver, CO.
18. Villaflor V, Won B, Nagy B et al. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer. Paper presented at the World Conference Lung Cancer (WCLC), 2015, ORAL 38.02; Denver, CO.
19. Mack PC, Gandara D, Lara P et al. Identification of actionable tumor alterations in circulating cellfree tumor DNA (cfDNA) using digital sequencing from NSCLC patients. Paper presented at theWorld Conference Lung Cancer (WCLC), 2015, ORAL 38.06; Denver, CO.
20. Goto K, Ichinose Y, Ohe Y et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: From IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in nonsmall cell lung cancer. J Thorac Oncol 2012;7: 115-121.
21. Kimura H, Kasahara K, Kawaishi M et al. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer. Clin Cancer Res 2006;12:3915-3921.
22. Bai H, Mao L, Wang HS et al. Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer. J Clin Oncol 2009;27:2653-2659.
23. Brevet M, Johnson ML, Azzoli CG et al. Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 2011;73: 96-102.
24. Jian G, Songwen Z, Ling Z et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin Oncol 2010;136:1341-1347.
25. Mok T, Wu YL, Lee JS et al. Detection and dynamic changes of EGFR mutations from circulating tumorDNAas a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy. Clin Cancer Res 2015; 21:3196-3203.
26. Tseng JS, Yang TY, Tsai CR et al. Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. J Thorac Oncol 2015;10:603-610.
27. Marchetti A, Palma JF, Felicioni L et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of NSCLC patients. J Thorac Oncol 2015; 10:1437-1443.
28. Newman AM, Bratman SV, To J et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014;20:548-554.
29. Karachaliou N, Mayo-delas Casas C, Queralt C et al. Association of EGFR L858R mutation in circulating free DNA with survival in the EURTAC trial. JAMA Oncol 2015;1:149-157.
30. Kuang Y, Rogers A, Yeap BY et al. Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer. Clin Cancer Res 2009;15:2630-2636.
31. Sequist L, Goldman JW, Wakelee HA et al. Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive NSCLC patients. J Clin Oncol 2015; 33((suppl)):8001a.
32. Husain H, Kosco K, Vibat CRT et al. Kinetic monitoring of EGFR T790M in urinary circulating tumor DNA to predict radiographic progression and response in patients with metastatic lung adenocarcinoma. J Clin Oncol 2015;33:8081a.
33. Wang Z, Chen R, Wang S et al. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFRTKI treatment in advanced NSCLC. PLoS One 2014;9: e110780.
34. Sorensen BS, Wu L, Wei W et al. Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 2014;120:3896-3901.
35. Gregorc V, Novello S, Lazzari C et al. Predictive value of a proteomic signature in patients with nonsmall-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): A biomarkerstratified, randomised phase 3 trial. Lancet Oncol 2014;15:713-721.
36. Carbone DP, Ding K, Roder H et al. Prognostic and predictive role of the VeriStrat plasma test in patients with advanced non-small-cell lung cancer treated with erlotinib or placebo in the NCIC Clinical Trials Group BR.21 trial. J Thorac Oncol 2012;7: 1653-1660.
37. Stinchcombe TE, Roder J, Peterman AH et al. A retrospective analysis of VeriStrat status on outcome of a randomized phase II trial of first-line therapy with gemcitabine, erlotinib, or the combination in elderly patients (age70years or older) with stage IIIB/IV non-small-cell lung cancer. J Thorac Oncol 2013;8:443-451.
38. Taguchi F, Solomon B, Gregorc V et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: A multicohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
39. Cortinovis D, Monica V, Pietrantonio F et al. MicroRNAs in non-small cell lung cancer: Current status and future therapeutic promises. Curr Pharm Des 2014;20:3982-3990.
40. Mitchell PS, Parkin RK, Kroh EM et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105: 10513-10518.
41. Shen J, Todd NW, Zhang H et al. Plasma microRNAs as potential biomarkers for non-smallcell lung cancer. Lab Invest 2011;91:579-587.
42. Hennessey PT, Sanford T, Choudhary A et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One 2012;7: e32307.
43. Leidinger P, Brefort T, Backes C et al. Highthroughput qRT-PCR validation of blood microRNAs in non-small cell lung cancer. Oncotarget 2016;7: 4611-4623.
44. Chen X, Hu Z, Wang W et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 2012;130:1620-1628.
45. Boeri M, Verri C, Conte D et al. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci USA 2011; 108:3713-3718.
46. Sozzi G, Boeri M, Rossi M et al. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: A correlative MILD trial study. J Clin Oncol 2014;32: 768-773.
47. Bianchi F, Nicassio F, Marzi M et al. A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol Med 2011;3:495-503.
48. Hu Z, Chen X, Zhao Y et al. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 2010;28: 1721-1726.
49. Zheng D, Haddadin S, Wang Y et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-586.
50. Gumireddy K, Li A, Chang DH et al. AKAP4 is a circulating biomarker for non-small cell lung cancer. Oncotarget 2015;6:17637-17647.
51. Nagrath S, Sequist LV, Maheswaran S et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450: 1235-1239.
52. Allan AL, Keeney M. Circulating tumor cell analysis: Technical and statistical considerations for application to the clinic. J Oncol 2010;2010:426218.
53. Yu N, Zhou J, Cui F et al. Circulating tumor cells in lung cancer: Detection methods and clinical applications. Lung 2015;193:157-171.
54. Wang B et al. Clinical test on circulating tumor cells in peripheral blood of lung cancer patients, based on novel immunomagnetic beads. Artif Cells Nanomed Biotechnol 2016;44:892-897.
55. Vona G, Sabile A, Louha M et al. Isolation by size of epithelial tumor cells: A new method for the immunomorphological andmolecular characterization of circulating tumor cells. Am J Pathol 2000;156: 57-63.
56. Breitenbuecher F, Hoffarth S, Worm K et al. Development of a highly sensitive and specific method for detection of circulating tumor cells harboring somatic mutations in non-small-cell lung cancer patients. PLoS One 2014;9:e85350.
57. Maheswaran S, Sequist LV, Nagrath S et al. Detection of mutations in EGFR in circulating lungcancer cells. N Engl JMed 2008;359:366-377.
58. Ilie M, Long E, Butori C et al. ALK-gene rearrangement: A comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012;23: 2907-2913.
59. Pailler E, Adam J, Barthélémy A et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013;31:2273-2281.
60. Pailler E, Auger N, Lindsay CR et al. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer. Ann Oncol 2015;26:1408-1415.
61. Hou JM, Krebs MG, Lancashire L et al. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer. J Clin Oncol 2012;30:525-532.
62. Krebs MG, Sloane R, Priest L et al. Evaluation andprognostic significance of circulatingtumorcells in patients with non-small-cell lung cancer. J Clin Oncol 2011;29:1556-1563.
63. Farace F, Massard C, Vimond N et al. A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011;105:847-853.
64. Hofman VJ, Long E, Ilie M et al. Morphological analysis of circulating tumour cells in patients undergoing surgery for non-small cell lung carcinoma using the isolation by size of epithelial tumour cell (ISET) method. Cytopathology 2012;23:30-38.
65. Li J, Shi SB, Shi WL et al. LUNX mRNA-positive cells at different time points predict prognosis in patients with surgically resected nonsmall cell lung cancer. Transl Res 2014;163:27-35.
66. Inal C, Yilmaz E, Cheng H et al. Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a communitybased academic center. J Clin Oncol 2014;32(suppl 5):8098a.
67. Lim C, Sung M, Shepherd FA et al. Patients with advanced non-small cell lung cancer: Are research biopsies a barrier to participation in clinical trials. J Thorac Oncol 2016;11:79-84.
68. Kimura H, Kasahara K, Shibata K et al. EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer. J Thorac Oncol 2006;1:260-267.
69. Yung TK, Chan KC, Mok TS et al. Singlemolecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res 2009;15:2076-2084.
70. Mack PC, Holland WS, Burich RA et al. EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxeltreated non-small cell lung cancer. J Thorac Oncol 2009;4:1466-1472.
71. He C, Liu M, Zhou C et al. Detection of epidermal growth factor receptor mutations in plasma bymutant-enrichedPCR assay for prediction of the response to gefitinib in patients with nonsmall-cell lung cancer. Int J Cancer 2009;125: 2393-2399.
72. Jiang B, Liu F, Yang L et al. Serum detection of epidermal growth factor receptor gene mutations using mutant-enriched sequencing in Chinese patients with advanced non-small cell lung cancer. J Int Med Res 2011;39:1392-1401.
73. Sriram KB, Tan ME, Savarimuthu SM et al. Screening for activating EGFRmutations in surgically resectednonsmall cell lung cancer. Eur Respir J 2011; 38:903-910.
74. Xu F, Wu J, Xue C et al. Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets Ther 2012;5: 439-447.
75. Huang Z, Wang Z, Bai H et al. The detection of EGFR mutation status in plasma is reproducible and can dynamically predict the efficacy of EGFR-TKI. Thoracic Cancer 2012;3:334-340.
76. Zhang H, Liu D, Li S et al. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology. J Mol Diagn 2013;15:819-826.
77. Liu X, Lu Y, Zhu G et al. The diagnostic accuracy of pleural effusion and plasma samples versus tumour tissue for detection of EGFR mutation in patients with advanced non-small cell lung cancer: Comparison of methodologies. J Clin Pathol 2013; 66:1065-1069.
78. Kim ST, Jung HY, Sung JS et al. Can serum be used for analyzing the EGFR mutation status in patients with advanced non-small cell lung cancer? Am J Clin Oncol 2013;36:57-63.
79. Kim HR, Lee SY, Hyun D S et al. Detection of EGFR mutations in circulating free DNA by PNA-mediated PCR clamping. J Exp Clin Cancer Res 2013;32:50.
80. Zhao X, Han RB, Zhao J et al. Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients. Respiration 2013;85: 119-125.
81. Wang S, Han X, Hu X et al. Clinical significance of pretreatment plasma biomarkers in advanced nonsmall cell lung cancer patients. Clin Chim Acta 2014; 430:63-70.
82. Jing CW, Wang Z, Cao HX et al. High resolution melting analysis for epidermal growth factor receptormutations in formalin-fixed paraffin-embedded tissue and plasma free DNA from non-small cell lung cancer patients. Asian Pac J Cancer Prev 2014;14: 6619-6623.
83. Weber B, Meldgaard P, Hager H et al. Detection of EGFR mutations in plasma and biopsies from nonsmall cell lung cancer patients by allele-specific PCR assays. BMC Cancer 2014;14:294.
84. Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012;138: 2045-2050.
85. Le HB, Zhu WY, Chen DD et al. Evaluation of dynamic change of serummiR-21 andmiR-24 in preand post-operative lung carcinoma patients. Med Oncol 2012;29:3190-3197.
86. Liu XG, Zhu WY, Huang YY et al. High expression of serum miR-21 and tumor miR-200c associated with poor prognosis in patients with lung cancer. Med Oncol 2012;29:618-626.
87. Tang D, Shen Y, Wang M et al. Identification of plasmamicroRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev 2013;22:540-548.
88. Li M, Zhang Q, Wu L et al. Serum miR-499 as a novel diagnostic and prognostic biomarker in nonsmall cell lung cancer. Oncol Rep 2014;31: 1961-1967.
89. Yu D, Du K, Liu T et al. Prognostic value of tumor markers, NSE, CA125 and SCC, in operable NSCLC patients. Int JMol Sci 2013;14:11145-11156.
90. Geng Q, Fan T, Zhang B et al. Five microRNAs in plasma as novel biomarkers for screening of earlystage non-small cell lung cancer. Respir Res 2014;15: 149.
91. Tejero R, Navarro A, Campayo M et al. miR-141 and miR-200c as markers of overall survival in early stage non-small cell lung cancer adenocarcinoma. PLoS One 2014;9:e101899.
92. Powrózek T, Krawczyk P, Kowalski DM et al. Plasma circulatingmicroRNA-944 andmicroRNA-3662 as potential histologic type-specific early lung cancer biomarkers. Transl Res 2015;166: 315-323.
93. Wozniak MB, Scelo G, Muller DC et al. Circulating microRNAs as non-invasive biomarkers for early detection of non-small-cell lung cancer. PLoS One 2015;10:e0125026.
94. Powrózek T, Krawczyk P, Kowalski DM et al. Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer. Tumour Biol 2016;37: 2049-2055.
95. Wang RJ, Zheng YH, Wang P et al. Serum miR-125a-5p, miR-145 and miR-146a as diagnostic biomarkers in non-small cell lung cancer. Int J Clin Exp Pathol 2015;8:765-771.
96. Yang JS, Li BJ, Lu H W et al. SerummiR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. Tumour Biol 2015;36:3035-3042.